182 related articles for article (PubMed ID: 37885041)
1. Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen.
Schmutz M; Zucknick M; Schlenk RF; Mertens D; Benner A; Weichenhan D; Mücke O; Döhner K; Plass C; Bullinger L; Claus R
Clin Epigenetics; 2023 Oct; 15(1):171. PubMed ID: 37885041
[TBL] [Abstract][Full Text] [Related]
2. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation.
Füller M; Klein M; Schmidt E; Rohde C; Göllner S; Schulze I; Qianli J; Berdel WE; Edemir B; Müller-Tidow C; Tschanter P
Int J Oncol; 2015 Mar; 46(3):1192-204. PubMed ID: 25501798
[TBL] [Abstract][Full Text] [Related]
3. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.
Qu X; Davison J; Du L; Storer B; Stirewalt DL; Heimfeld S; Estey E; Appelbaum FR; Fang M
Epigenetics; 2015; 10(6):526-35. PubMed ID: 25996682
[TBL] [Abstract][Full Text] [Related]
4. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
[TBL] [Abstract][Full Text] [Related]
5. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.
Negrotto S; Ng KP; Jankowska AM; Bodo J; Gopalan B; Guinta K; Mulloy JC; Hsi E; Maciejewski J; Saunthararajah Y
Leukemia; 2012 Feb; 26(2):244-54. PubMed ID: 21836612
[TBL] [Abstract][Full Text] [Related]
6. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.
Akalin A; Garrett-Bakelman FE; Kormaksson M; Busuttil J; Zhang L; Khrebtukova I; Milne TA; Huang Y; Biswas D; Hess JL; Allis CD; Roeder RG; Valk PJ; Löwenberg B; Delwel R; Fernandez HF; Paietta E; Tallman MS; Schroth GP; Mason CE; Melnick A; Figueroa ME
PLoS Genet; 2012; 8(6):e1002781. PubMed ID: 22737091
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
8. Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
Gebhard C; Glatz D; Schwarzfischer L; Wimmer J; Stasik S; Nuetzel M; Heudobler D; Andreesen R; Ehninger G; Thiede C; Rehli M
Leukemia; 2019 Jan; 33(1):26-36. PubMed ID: 29925905
[TBL] [Abstract][Full Text] [Related]
9. A Pilot Study of Aberrant CpG Island Hypermethylation of
Sun J; Zhang J; Wang Y; Li Y; Zhang R
Int J Med Sci; 2019; 16(2):324-330. PubMed ID: 30745814
[No Abstract] [Full Text] [Related]
10. Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia.
Huang J; Liu Z; Sun Y; Zhong Q; Xu L; Ou R; Li C; Chen R; Yao M; Zhang Q; Liu S
Int J Mol Med; 2018 Feb; 41(2):679-686. PubMed ID: 29207054
[TBL] [Abstract][Full Text] [Related]
11. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Bohl SR; Bullinger L; Rücker FG
Expert Rev Hematol; 2018 May; 11(5):361-371. PubMed ID: 29543073
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
[TBL] [Abstract][Full Text] [Related]
14. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.
He S; Li Y; Wang L; Li Y; Xu L; Cai D; Zhou J; Yu L
Neoplasia; 2024 Mar; 49():100965. PubMed ID: 38245923
[TBL] [Abstract][Full Text] [Related]
16. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
[TBL] [Abstract][Full Text] [Related]
17. Region-Specific Methylation Profiling in Acute Myeloid Leukemia.
Cecotka A; Polanska J
Interdiscip Sci; 2018 Mar; 10(1):33-42. PubMed ID: 29405013
[TBL] [Abstract][Full Text] [Related]
18. A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjects.
McClay JL; Aberg KA; Clark SL; Nerella S; Kumar G; Xie LY; Hudson AD; Harada A; Hultman CM; Magnusson PK; Sullivan PF; Van Den Oord EJ
Hum Mol Genet; 2014 Mar; 23(5):1175-85. PubMed ID: 24135035
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia.
He S; Li Y; Shi X; Wang L; Cai D; Zhou J; Yu L
Clin Epigenetics; 2023 Mar; 15(1):37. PubMed ID: 36864492
[TBL] [Abstract][Full Text] [Related]
20. High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias.
Magi A; Mattei G; Mingrino A; Caprioli C; Ronchini C; Frigè G; Semeraro R; Bolognini D; Rambaldi A; Candoni A; Colombo E; Mazzarella L; Pelicci PG
Commun Biol; 2023 Apr; 6(1):382. PubMed ID: 37031307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
